Dale Michalak
Family Medicine · Worthington, OHNPI 1972500494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Pfizer at 24.3% of the total. Reporting peaked in 2021 at $691 and has fallen 95.3% since, to $33 in 2023.
Across 112 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$396
- AstraZeneca$262
- Novo Nordisk$210
- AbbVie$209
- Amgen$109
- Amarin Pharma, Inc.$88
- plus $353 from 13 others
What the payments were for
- Food & beverage$1,626100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $396 |
| AstraZeneca | 19 | $262 |
| Novo Nordisk | 15 | $210 |
| AbbVie(2 entities) | 17 | $209 |
| Amgen(2 entities) | 8 | $109 |
| Amarin Pharma, Inc. | 5 | $88 |
| Merck | 5 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Boehringer Ingelheim | 3 | $37 |
| Eisai Inc. | 2 | $34 |
| Abbott | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Johnson & Johnson | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
| GSK | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$1,626 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 17 | $305 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Worthington
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.